Skip to main content

Sexual health hub

Sex, intimacy, and the changes no one warned you about

However you got here—perimenopause, years after menopause, surgery, illness or a change in what feels good—there's room for your version of sex and intimacy. Start with comfort, desire, pleasure or a question for your doctor; partnered, solo, or not interested, you belong here.

The sexual-health tools linked here save logs on this device, without account sync. You decide whether to share an export. Other Hello Nila features, including signed-in Track, account journals and chat, use server storage; see the privacy notice.

Comfort matters. Pleasure counts. And wanting less doesn't mean you need fixing.

You might be here for dryness, pain, a change in desire, or just a better conversation about sex. You don't need a cancer diagnosis, a partner, or a particular level of desire to use this page.

43.1%

Reported a sexual problem in the PRESIDE survey of 31,581 US women.

2008PRESIDE, Shifren et al.

How to read the grades

Strong evidence from multiple high-quality studies. Nila is confident in these takeaways.
Good evidence, but limited sample size. Nila notes where the gaps are so you can ask smarter questions.
Emerging or limited evidence. Useful context, but treat conclusions as provisional.
Claim outpaces the data. Common online, thin in the literature. We name it as such so you can decide.

Start where you are

Use the words for your body that feel right; we follow anatomy, not identity.

Pick what sounds like you

The 4 Core Guides

Comfort, desire and care—start where you need it

Four places to begin, whether changes arrived gradually or all at once. Treatment-specific cautions stay with the options they affect.

Genital and urinary changes of menopause (GSM: dryness, irritation, urgency, recurrent UTIs) affect somewhere between 13% and 87% of people, depending on how studies ask. They tend to continue without treatment rather than fade.

The range is wide because studies define GSM differently and ask about different symptoms.

Low-dose vaginal estrogen is the best-supported treatment in the 2025 AUA/SUFU/AUGS guideline, and guidelines recommend it to lower recurrent UTI risk. After hormone-positive breast cancer, decisions are individual. Moisturizers (used regularly), lubricants (for sex), dilators for narrowing, and pelvic floor work are non-hormonal tools. Skip fragranced washes.

Try the pelvic health practices
2025AUA/SUFU/AUGS GSM Guideline 2025
NICE NG112Prevalence range (CIDRAP)

Pain is common, and it's not something you have to push through. It can be entry pain, deep pain, burning after, or bladder urgency after sex. Common contributors: dryness and a pH shift, pelvic floor holding after surgery or radiation, low estrogen, bracing from anxiety, and less time for arousal.

Small things help: more time for arousal, an unclenched jaw, breathing out longer than in (in for 4, out for 6), water-based or silicone lube, changing angle, pausing. If pain is new or severe, or comes with bleeding, get seen the same day.

Open the pelvic floor workbook
2025Kobiella et al., Supportive Care in Cancer

The cited pain source comes from cancer-care research. It doesn't establish the same treatment effects for everyone in midlife.

Pain with sex

If sex hurts, you don't have to push through it.

2026-09-15MREF: Menopause, sex and pain (PDF)

Desire lives in brain, body and context.

The PRESIDE survey of 31,581 US women found 43.1% reported a sexual problem and 22.2% felt distressed about sex. Distressing problems peaked at midlife, 14.8% at ages 45 to 64. Desire that was frequent can feel distant. That's grief and physiology, not failure. Tracking patterns, not scores, helps you see what shifts it.

2008PRESIDE, Shifren et al.

A 2025 study of primary care records found female sexual dysfunction was diagnosed and managed less often than erectile dysfunction. You may need to open the door.

Bring your symptom pattern from Nila, the body map with spots circled, the treatments you've tried, and what matters to you. Plain words work: “I have pain at entry after chemo.” “I've had UTIs every month since menopause.” “Desire is gone and it's distressing.”

Download the waiting-room kit
2025Stanley et al., J Gen Intern Med

When cancer or treatment is part of your storyCopy link to this section

A dedicated place for cancer treatment, risk-reducing ovary removal and abrupt menopause—within the wider midlife picture.

Your treatment history can change which options fit. Keep your oncology or surgical team in the conversation; the cautions in the guides above still apply.

74%

Met criteria for sexual dysfunction in one study of 119 people after RRSO. This finding is specific to that study, not everyone in midlife.

Cancer treatment and risk-reducing ovary removal (RRSO) can change hormones, anatomy and the nervous system all at once. In one study of 119 people after RRSO, 74% met criteria for sexual dysfunction and 73% for low desire. Among gynecologic cancer survivors, sexual changes are common, and rates run higher after surgery combined with radiation.

That's not in your head. It can be dryness, narrowing, pain, altered arousal, and desire that doesn't match your body yet. After hormone-positive breast cancer, systemic hormone therapy is often off the table, so local options need a careful talk with your oncology team.

2016 and 2022Tucker et al., Gynecologic Oncology
Chang et al., Supportive Care in Cancer

After surgery or abrupt menopause

Desire lives in brain, body and context. After abrupt menopause, estrogen, progesterone and testosterone fall fast. Sleep is broken, mood is buzzy, confidence feels thinner.

Why this hub exists

More than 43% of US women in the PRESIDE survey reported a sexual problem, yet in primary care, female sexual dysfunction is diagnosed and managed less often than erectile dysfunction. After risk-reducing ovary removal, one study found 74% met criteria for sexual dysfunction. The map is crowded at diagnosis and empty after it. This is the after part.

Most trackers give you a score. We read it back to you. Desire, arousal, dryness, pain, UTIs, mood and sleep, over time, in your words. No readiness scores. No selling your data. Your patterns, remembered.

“I went into chemical menopause overnight, then surgical menopause the same day they finally found endo after 18 years. No slow transition. No easing in. Just acute, all-at-once menopause with a body I was still learning. This site is the place I wish I'd had open.”

Erin Beattie, founder

Sexual health: research and resourcesCopy link to this section

Different questions, different evidence. Read the originals, with a little context before you go.

Desire, comfort and pleasure don't come down to one hormone number. These reviews look at connected influences and people's experiences, not a score to meet or proof that one treatment works for everyone.

Systematic review · associations, not treatment effects

Biopsychosocial correlates and predictors of sexual function in perimenopause: a systematic review

Kolbuszewska et al · The Journal of Sexual Medicine · 2026

Across 42 studies of perimenopausal women, genital and urinary symptoms, psychological distress and relationship factors were associated with sexual function. Hormone-level associations were inconsistent or absent. Most studies were cross-sectional, so the review cannot establish cause or which treatment works. Measures and menopause-stage definitions varied.

Read the original research

Qualitative review · experiences, not treatment effects

Women’s experiences of their sexuality during their menopausal transition and the support offered to them by healthcare providers: A systematic review and meta-synthesis

Calvin, Cina, Byrskog, Erlandsson and Borneskog · European Journal of Midwifery · 2025

Brings together 21 qualitative studies involving 610 women. Accounts varied with relationships, personal priorities and how menopause was understood; some participants wanted more information and support from care. This is lived-experience research, not a test of treatment or a prevalence estimate. Only one included study represented non-heterosexual participants, and menopause stages were not consistently defined; it cannot represent every gender or relationship.

Read the original research

Patient information · free to read

Sexual Health

The Menopause Society

An overview of desire, arousal, orgasm, dryness and pain, and talking about care. There isn't one required level of desire or frequency of sex. General education, not a treatment trial; medicine approvals and availability can change, so check current local prescribing advice.

Open resource

For clinicians · paid reference book

A Practical Guide to Female Sexual Medicine

Corey R. Babb · CRC Press · 2025 · first edition

A clinical reference covering desire, arousal, sexual pain, orgasm, assessment and management. This links to the publisher, not a free full-text book or a formal guideline. The full book hasn't been reviewed here; listing it doesn't mean Corey reviewed this Nila guide.

Open resource

TrackersCopy link to this section

Bacterial vaginosis, yeast and UTIs come back by nature. Few tools track recurrence. We do.

Tracking patterns, not scores, helps you see what shifts it.

Your private pattern

Nothing logged yet. Log a day and your last 7 days show here, read only on this device.

Device storage details

Sample view | Bridge: Web fallback | Store: IndexedDB | Last sync: not yet

Tracker 1

Recurrence Tracker — BV, Yeast, UTIs

Recurrence is the pattern everyone misses

123456789101112131415161718192021222324252627282930
What came back?
Symptoms (optional)
Anything before it? (optional)
Pain, 0 to 10

Saved only on this device. No account sync, no analytics. Clearing your browser removes it.
Saved only on this device. We don't see it, sell it, or train on it. Clear anytime.

Tracker 2

Intimacy Tracker

Desire, arousal, pain, sleep: tracked over time, not scored

Desire today
Arousal
Orgasm
Pain, 0 to 10
Lubrication

Saved only on this device. No account sync, no analytics. Clearing your browser removes it.
Saved only on this device. We don't see it, sell it, or train on it. Clear anytime.

Some devices became HSA/FSA eligible in 2022. Being FDA-registered as a low-risk device isn't the same as being cleared or proven. FDA has said no energy-based vaginal rejuvenation device (laser or radiofrequency) is cleared or approved for menopause symptoms, incontinence or sexual function, and their safety and effectiveness aren't established.

Where the evidence is strongest, it isn't about pleasure. The best-studied items here are the plain ones for bladder leaks: weighted cones, a pelvic floor trainer, and an in-clinic chair. Their trials measured leakage and quality of life, not arousal, and most didn't look at menopause specifically. Read the grades with that in mind.

FDA statement, July 30, 2018

Lioness

Lioness smart vibrator

FDA status
Consumer wellness product, no FDA clearance
What it claims
Biofeedback that shows pelvic floor activity during arousal and orgasm.
What evidence exists
One study of 54 people (J Sex Med 2022) using data from the device, with company co-authors.
Who it may not be for
Treating pain or GSM. It's a pleasure and self-knowledge tool.
Maker's site ↗
Read full review
FDA status
Consumer wellness product, no FDA clearance
HSA/FSA
Not confirmed
What it claims
Biofeedback that shows pelvic floor activity during arousal and orgasm.
What evidence exists
One study of 54 people (J Sex Med 2022) using data from the device, with company co-authors.
Who it may not be for
Treating pain or GSM. It's a pleasure and self-knowledge tool.
2022Pfaus et al., J Sex Med

Several brands, including EvaCare (Personal Med)

Weighted vaginal cones

FDA status
Sold over the counter, made in an FDA-registered facility, not cleared for a specific claim
What it claims
Small weights you hold inside the vagina for 15 to 20 minutes a day to train the pelvic floor.
What evidence exists
Two independent randomized trials found cones helped: 107 women in the BMJ in 1999, and 118 in Brazil in 2008. Both compared cones with no treatment and found less leakage and better quality of life, in line with doing the exercises unaided. Neither trial was about menopause specifically.
Who it may not be for
Pain, or a pelvic floor that won't relax. Cones train a weak floor, not an over-tight one.
Maker's site ↗
Read full review
FDA status
Sold over the counter, made in an FDA-registered facility, not cleared for a specific claim
HSA/FSA
Not confirmed
What it claims
Small weights you hold inside the vagina for 15 to 20 minutes a day to train the pelvic floor.
What evidence exists
Two independent randomized trials found cones helped: 107 women in the BMJ in 1999, and 118 in Brazil in 2008. Both compared cones with no treatment and found less leakage and better quality of life, in line with doing the exercises unaided. Neither trial was about menopause specifically.
Who it may not be for
Pain, or a pelvic floor that won't relax. Cones train a weak floor, not an over-tight one.
Try the free practices first →
1999 and 2008Castro et al., Clinics (Sao Paulo), 2008 randomized trial

BTL Industries (in-clinic chair)

Emsella

FDA status
FDA-cleared as a nonimplanted electrical continence device for urinary incontinence (K241516, February 2025)
What it claims
A chair you sit on fully clothed that uses focused electromagnetic energy to contract the pelvic floor thousands of times a session, for leakage, and in some markets for sexual function.
What evidence exists
A 2025 systematic review and meta-analysis of seven studies found fewer leakage episodes and better quality-of-life scores than control, but no clear change in muscle tone. Most included studies were small and linked to the maker. The '7x more effective than pelvic floor training' figure is BTL's own, from a press release, not a published comparison. Our fuller read: promising, not proven.
Who it may not be for
Anyone after a one-off fix, or anyone told the chair replaces pelvic floor physio. It's a course of clinic sessions, and the sexual-function licence is newer and thinner than the incontinence one.
Maker's site ↗
Read full review
FDA status
FDA-cleared as a nonimplanted electrical continence device for urinary incontinence (K241516, February 2025)
HSA/FSA
Not confirmed, ask your clinic
What it claims
A chair you sit on fully clothed that uses focused electromagnetic energy to contract the pelvic floor thousands of times a session, for leakage, and in some markets for sexual function.
What evidence exists
A 2025 systematic review and meta-analysis of seven studies found fewer leakage episodes and better quality-of-life scores than control, but no clear change in muscle tone. Most included studies were small and linked to the maker. The '7x more effective than pelvic floor training' figure is BTL's own, from a press release, not a published comparison. Our fuller read: promising, not proven.
Who it may not be for
Anyone after a one-off fix, or anyone told the chair replaces pelvic floor physio. It's a course of clinic sessions, and the sexual-function licence is newer and thinner than the incontinence one.
Read our full read of the chair →
2025HIFEM meta-analysis, Neurourology and Urodynamics

X6 Innovations

Perifit Care and Care+

FDA status
Consumer kegel trainer, not FDA-cleared as a treatment
What it claims
A probe or wearable that shows your pelvic floor contractions in an app, so you train with feedback.
What evidence exists
The strongest evidence here is a 2025 Cochrane review of randomized trials: adding biofeedback to pelvic floor training made little or no difference to leakage, quality of life, or how often people felt cured, compared with doing the exercises alone. The company's own real-world study of 6,060 women had no control group.
Who it may not be for
Anyone on a tight budget. The exercises are free, and the review says the gadget adds little to them.
Maker's site ↗
Read full review
FDA status
Consumer kegel trainer, not FDA-cleared as a treatment
HSA/FSA
Not confirmed
What it claims
A probe or wearable that shows your pelvic floor contractions in an app, so you train with feedback.
What evidence exists
The strongest evidence here is a 2025 Cochrane review of randomized trials: adding biofeedback to pelvic floor training made little or no difference to leakage, quality of life, or how often people felt cured, compared with doing the exercises alone. The company's own real-world study of 6,060 women had no control group.
Who it may not be for
Anyone on a tight budget. The exercises are free, and the review says the gadget adds little to them.
The free version of this training →
2025Cochrane review CD009252, 2025

We only list products with published research behind them (graded B or C). Products backed only by company claims or company-funded studies are left out. No paid placements, no affiliate links, and makers can't buy a grade.

Suggest a device to review

Low desire that causes distress (hypoactive sexual desire disorder, HSDD) is common after menopause. One large survey found it in about 9% after natural menopause and up to 26% in younger people after surgical menopause. Until recently, both approved medicines, Addyi (flibanserin) and Vyleesi (bremelanotide), were only for premenopausal use.

On December 15, 2025, FDA expanded Addyi to people under 65 regardless of menopause status, the first oral option for HSDD after menopause. It isn't a performance drug. Vyleesi is still approved for premenopausal use only. There's no FDA-approved testosterone for women, and off-label prescribing comes with access barriers. Non-drug supports matter too: sleep, pain care, sex therapy and time.

  1. 2015

    Addyi approved for premenopausal HSDD.

  2. 2019

    Vyleesi approved for premenopausal HSDD.

  3. December 15, 2025

    Addyi expanded to under-65s regardless of menopause status.

2025-12-15FDA approval letter
HSDD prevalence, WISHeS study (2006)

Related symptom guides:

Menopause doesn't happen to just one person in the house. It happens to the partner who doesn't know what to say, too.

So we made space for them.

  • Your person gets their own private Premium account
  • No card needed
  • No access to anything you log

Every Premium membership includes a +1: your person gets their own private Premium account, with no card needed and no access to anything you log. No awkward “can you download this?” conversation. You share the seat. They get tools, understanding and their own space.

We charge for one. We built for two.

Not sure where to start?

You don't need to do all of this. Pick one small next step.

  1. Log one day

    Pick the tracker that fits — recurrence or intimacy — and log today. Patterns show up faster than you think.

  2. Prep for your appointment

    Bring one clear sentence about what's happening and what matters to you.

  3. Start with one guide

    Choose the guide that sounds most like you — comfort, pain, desire, or after surgery.

Nothing here is saved, shared, or scored unless you choose to log it. This page is just for you.

The sexual-health tools linked here save logs on this device, without account sync. You decide whether to share an export. Other Hello Nila features, including signed-in Track, account journals and chat, use server storage; see the privacy notice. How we handle data

Educational information, not medical advice. More sources in the research library.

Saved only on this device. We don't see it, sell it, or train on it. Clear anytime.